Jefferies & Company is out with a research report this morning, where it reiterates its Buy rating on ARIAD Pharmaceuticals ARIA; it has a $6.00 price target on the stock.
The Jefferies analysts said that the start of ARIA's Ph2 registration study of ponatinib is positive albeit expected, given strong efficacy data in 3rd-line CML/Ph+ALL and consultants' positive opinions. The next event is Ph3 data for ridaforolimus in advanced sarcoma in 4Q (by MRK); if positive, this would provide a significant upside to ARIA's current valuation/cash position.
The analysts noted that “ARIA expects ponatinib global sales of ~$600M w/in 5 years of launch in 2nd/3rd-line CML/Ph+ ALL, ~1/2 of the current market for dasatinib (~$551M est. in 2010) and nilotinib (~$380M in 2010).” This assumes ponatinib pricing at slight premium pricing vs. dasatinib/nilotinib (annual Tx cost of ~$83K/~$89K, respectively).
The analyst also note that the company's cash balance of ~$45M at YE10 is sufficient to get the company through 2H11, but may not be sufficient to complete the PACE trial.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in